BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.81 USD
-0.43 (-34.68%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.70%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for BRIACELL THERAP falls in the month of July .
All items in Millions except EPS data.
7/31/24 | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 23 | 15 | 7 | 4 |
Income After Depreciation & Amortization | 0 | -23 | -15 | -7 | -4 |
Non-Operating Income | NA | 3 | -12 | 7 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -20 | -27 | 0 | -4 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -20 | -27 | 0 | -4 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -20 | -27 | 0 | -4 |
Depreciation Footnote | 7/31/24 | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -23 | -15 | -7 | -4 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -23 | -15 | -7 | -4 |
Earnings Per Share Data | 7/31/24 | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 15.62 | 15.49 | 4.52 | 0.71 |
Diluted EPS Before Non-Recurring Items | NA | -1.30 | -1.73 | -0.09 | -5.20 |
Diluted Net EPS (GAAP) | NA | -1.30 | -1.73 | -0.09 | -5.20 |
Fiscal Year end for BRIACELL THERAP falls in the month of July .
All items in Millions except EPS data.
7/31/24 | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.23 | 9.83 | 8.51 | 7.71 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.23 | -9.83 | -8.51 | -7.71 |
Non-Operating Income | NA | 10.92 | -0.02 | 14.46 | -2.11 |
Interest Expense | NA | 0.00 | 1.49 | 0.00 | -7.40 |
Pretax Income | NA | 1.69 | -11.33 | 5.96 | -2.42 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.02 | -0.04 | -0.04 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 1.69 | -11.33 | 5.96 | -2.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 1.72 | -11.29 | 6.00 | -2.42 |
Earnings Per Share Data | 7/31/24 | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 15.98 | 15.98 | 16.68 | 15.62 |
Diluted EPS Before Non-Recurring Items | NA | 0.11 | -0.71 | -0.50 | -0.15 |
Diluted Net EPS (GAAP) | NA | 0.11 | -0.71 | -0.50 | -0.14 |